The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...

President Donald Trump's nominee for NIH director, Dr Jay Bhattacharya, fielded intense questioning on vaccines and cuts to ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they both slowed the progression of the memory-robbing illness.

“This study adds to our understanding of how menopause may relate to brain health for women in later life. It suggests that women who experience more menopausal symptoms, report greater cognitive and ...

After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Record Net Revenue at 2,736 million euros, +1.5% Strong contribution to Net Revenue from acquisitions at +2.5% Adjusted EBIT ...

Lecanemab is an antibody infusion therapy, developed by pharmaceutical company Eisai, which has been shown to slow cognitive decline in the early stages of Alzheimer's disease. The drug is ...